Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Myeloproliferative Disorders × Hydroxyzine × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Vulvar Neoplasms 1 Vulvar Diseases 1 Uterine Cervical Dysplasia 1 Papillomavirus Infections 1 Myeloproliferative Disorders 1 Carcinoma in Situ 1

Interventions

fludarabine 18 Whole-Body Irradiation 15 Cyclophosphamide 15 ruxolitinib 14 fludarabine phosphate 12 Tacrolimus 11 Specimen Handling 11 Mycophenolic Acid 11 Biopsy 10 Azacitidine 10 venetoclax 8 Peripheral Blood Stem Cell Transplantation 8 Melphalan 8 Cytarabine 8 Busulfan 7 Injections 6 Stem Cell Transplantation 5 Sirolimus 5 Daunorubicin 5 CPX-351 5 luspatercept 4 itacitinib 4 fedratinib 4 decitabine and cedazuridine drug combination 4 Liposomes 4 Granulocyte Colony-Stimulating Factor 4 ivosidenib 3 Thiotepa 3 Methotrexate 3 Cyclosporine 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03808805 2025-12-03

APHYPAP

University Hospital, Brest

Phase 3 Completed

Myeloproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon ⚡